Literature DB >> 22553997

Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.

Robert A Hong1, Kahealani K Rivera, Arksarapuk Jittirat, Joon J Choi.   

Abstract

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited condition associated with ventricular tachycardia (VT) triggered by exercise or sympathetic stress. Incessant VT may develop due to defibrillator-induced storming-a condition where implantable cardioverter-defibrillator discharges result in a hyperadrenergic state, provoking further VT and defibrillator discharge. We describe the case of a 14-year-old boy with CPVT caused by a calsequestrin-2 mutation, who presented with defibrillator-induced storming refractory to β-blockers, calcium-channel blockers, amiodarone, and dronedarone. Flecainide and β-blocker use suppressed incessant VT and defibrillator-induced storming. ©2012, The Authors. Journal compilation ©2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553997     DOI: 10.1111/j.1540-8159.2012.03421.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  8 in total

Review 1.  Therapeutic Strategies Targeting Inherited Cardiomyopathies.

Authors:  Kenneth Varian; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2017-08

2.  Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT).

Authors:  Carlo Napolitano; Raffaella Bloise; Mirella Memmi; Silvia Giuliana Priori
Journal:  Eur J Hum Genet       Date:  2013-04-03       Impact factor: 4.246

3.  The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Krystien Vv Lieve; Arthur A Wilde; Christian van der Werf
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 4.  The function and regulation of calsequestrin-2: implications in calcium-mediated arrhythmias.

Authors:  Elliot T Sibbles; Helen M M Waddell; Valeria Mereacre; Peter P Jones; Michelle L Munro
Journal:  Biophys Rev       Date:  2022-01-07

5.  Current and emerging antiarrhythmic drug therapy for ventricular tachycardia.

Authors:  Eric S Williams; Mohan N Viswanathan
Journal:  Cardiol Ther       Date:  2013-02-20

6.  Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload.

Authors:  Hyun Seok Hwang; Marcelo P Baldo; Jose Pindado Rodriguez; Michela Faggioni; Bjorn C Knollmann
Journal:  Front Physiol       Date:  2019-08-13       Impact factor: 4.566

7.  Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia.

Authors:  Henrik Eckert; Ibrahim El-Battrawy; Michael Veith; Gretje Roterberg; Jacqueline Kowitz; Siegfried Lang; Xiaobo Zhou; Ibrahim Akin; Andreas Mügge; Assem Aweimer
Journal:  J Pers Med       Date:  2022-03-28

Review 8.  Catecholaminergic polymorphic ventricular tachycardia: An exciting new era.

Authors:  Shashank P Behere; Steven N Weindling
Journal:  Ann Pediatr Cardiol       Date:  2016 May-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.